We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-11.01%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$645M
AUM Growth
+$36M
Cap. Flow
+$150M
Cap. Flow %
23.21%
Top 10 Hldgs %
72.39%
Holding
33
New
19
Increased
7
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$24.6M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$11.1M
3
EPIX
ESSA Pharma
EPIX
+$10.9M
4
EPZM
Epizyme, Inc
EPZM
+$9.97M
5
VSTM icon
Verastem
VSTM
+$8.65M

Top Sells

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$7.1M
2
ITOS
iTeos Therapeutics
ITOS
+$6.05M
3
RPTX
Repare Therapeutics
RPTX
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
2 Miscellaneous 5.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
26
Tectonic Therapeutic
TECX
$696M
$4.81M 0.75%
+71,822
New +$5.89M
LHDX
27
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$4.39M 0.68%
+578,114
New +$4.88M
RVMD icon
28
Revolution Medicines
RVMD
$44.6B
$4.13M 0.64%
+150,000
New +$4.37M
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$3.92M 0.61%
+400,000
New +$3.15M
INZY
30
DELISTED
Inozyme Pharma
INZY
$3.72M 0.58%
+320,724
New +$5M
AXSM icon
31
Axsome Therapeutics
AXSM
$10.4B
$3.63M 0.56%
+110,155
New +$4.29M
BDTX icon
32
Black Diamond Therapeutics
BDTX
$128M
$2.1M 0.33%
+248,506
New +$2.45M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2021 Portfolio in Review

As of Q3 2021, MPM BioImpact held 33 positions worth $645M, up 5.9% from $609M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

MPM BioImpact deployed $150M of net new capital in Q3 2021, opening 19 new positions and adding to 7 existing holdings. Its largest new stake was Intellia Therapeutics: 162,620 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Cullinan Oncology, an estimated $7.1M trimmed.

  • MPM BioImpact's largest Q3 2021 buy was Intellia Therapeutics: 162,620 shares worth $21.8M.
  • MPM BioImpact added most to Epizyme, Inc in Q3 2021, an estimated $9.97M increase.
  • MPM BioImpact's biggest Q3 2021 reduction was Cullinan Oncology, cutting an estimated $7.1M.
  • MPM BioImpact's ten largest holdings make up 72% of its $645M portfolio in Q3 2021.
  • MPM BioImpact opened 19 new positions and closed 0 in Q3 2021.
  • MPM BioImpact's portfolio value rose 5.9% quarter-over-quarter to $645M.

Based on MPM BioImpact's 13F filing for Q3 2021, filed 15 Nov 2021.